What is Leerink Partnrs’ Estimate for EW FY2026 Earnings?

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Leerink Partnrs upped their FY2026 EPS estimates for shares of Edwards Lifesciences in a research note issued to investors on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings per share of $2.90 for the year, up from their prior forecast of $2.87. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.57 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2028 earnings at $3.75 EPS.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue was up 8.9% on a year-over-year basis. During the same period last year, the business earned $0.59 earnings per share.

EW has been the subject of several other research reports. Barclays lowered their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Wells Fargo & Company dropped their target price on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Robert W. Baird reduced their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Finally, Daiwa America downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Seventeen investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $75.90.

Edwards Lifesciences Trading Up 0.7 %

Edwards Lifesciences stock opened at $72.06 on Tuesday. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a market capitalization of $42.50 billion, a price-to-earnings ratio of 10.40, a price-to-earnings-growth ratio of 4.01 and a beta of 1.12. The business’s fifty day simple moving average is $67.92 and its two-hundred day simple moving average is $75.35. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. The trade was a 11.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,000 shares of company stock worth $2,657,000. Company insiders own 1.27% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

A number of hedge funds have recently made changes to their positions in the business. First Community Trust NA bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $29,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the third quarter worth $30,000. Prospera Private Wealth LLC bought a new position in shares of Edwards Lifesciences during the third quarter worth $32,000. Avior Wealth Management LLC grew its stake in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. Finally, Webster Bank N. A. bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $39,000. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.